SCHEMBL2547232

SCHEMBL2547232

CCCn1cc(-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c2nccc(C)c21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 6/20 0.52
▸ CAMK2D Q13557 1/20 0.51
▸ FLT3 P36888 3/20 0.49
▸ JAK3 P52333 1/20 0.49
▸ CDK2 P24941 5/20 0.49
▸ MAPK8 P45983 3/20 0.49
▸ MAPK10 P53779 3/20 0.49
▸ CCNE1 P24864 2/20 0.49
▸ CDK1 P06493 3/20 0.47
▸ SMG1 Q96Q15 3/20 0.47
▸ CCNB1 P14635 1/20 0.47
▸ CDK7 P50613 1/20 0.47
▸ CCNH P51946 1/20 0.47
▸ MNAT1 P51948 1/20 0.47
▸ PLK4 O00444 1/20 0.46
▸ ACVR1 Q04771 1/20 0.45
▸ KDR P35968 1/20 0.45
▸ PTK2 Q05397 1/20 0.45
▸ MAPK9 P45984 1/20 0.44
▸ CCNT1 O60563 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2546585 0.91 JAK2 (0.55) JAK2CAMK2DFLT3JAK3CDK2
SCHEMBL2546325 0.91 CAMK2D (0.53) JAK2CAMK2DFLT3JAK3CDK2
SCHEMBL2545770 0.90 CAMK2D (0.51) CAMK2DFLT3CDK2CCNE1CDK1
SCHEMBL2541361 0.87 FLT3 (0.58) JAK2FLT3JAK3CDK2MAPK8
SCHEMBL2542388 0.83 CAMK2D (0.53) JAK2CAMK2DFLT3CDK2CCNE1
SCHEMBL2547226 0.83 FLT3 (0.67) JAK2CAMK2DFLT3JAK3CDK2
SCHEMBL2547332 0.82 JAK2 (0.53) JAK2CAMK2DFLT3JAK3CDK2
SCHEMBL2541859 0.81 CDK2 (0.53) JAK2FLT3JAK3CDK2MAPK8
SCHEMBL2546287 0.81 CAMK2D (0.53) CAMK2DFLT3CDK2CCNE1CDK1
SCHEMBL2540573 0.79 CDK1 (0.56) JAK2JAK3CDK2CDK1SMG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140303163-A1 USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER LUO YING (CN) 2014-10-09 — — US claimed
US-8309550-B2 Kinase inhibitors and their use as pharmaceutical agents SHANGHAI GENOMICS, INC. (CN) 2012-11-13 — — US claimed
WO-2012126181-A1 USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER LUO YING (CN) 2012-09-27 — — WO claimed
US-20110263541-A1 KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS SHANGHAI GENOMICS, INC (CN) 2011-10-27 — — US claimed
US-20140303163-A1 USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER LUO YING (CN) 2014-10-09 — — US disclosed
US-8309550-B2 Kinase inhibitors and their use as pharmaceutical agents SHANGHAI GENOMICS, INC. (CN) 2012-11-13 — — US disclosed
WO-2012126181-A1 USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER LUO YING (CN) 2012-09-27 — — WO disclosed
US-20110263541-A1 KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS SHANGHAI GENOMICS, INC (CN) 2011-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263541-A1 KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS MAP3K20, MAP3K1, MAP3K2 JAK2 178/4885CAMK2D 239/4885FLT3 388/4885
US-20140303163-A1 USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER NFKBIA, IRAK1, IRAK3 JAK2 184/4885CAMK2D 38/4885FLT3 1182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback